Compare Abeona Therapeutics Inc (ABEO) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Cisco Systems Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Cisco Systems Inc trades at $113.5 (market cap $440.61B). The key difference: Cisco Systems Inc is far larger — about 1180.2× Abeona Therapeutics Inc's market cap, and Cisco Systems Inc pays a 1.5% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CSCO | |
|---|---|---|
Market Cap | $373.32M | $440.61B |
Sector | Health | Technology |
52-Week High | $7.23 | $130.00 |
52-Week Low | $4.17 | $66.20 |
Enterprise Value | $228.22M | $455.28B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Cisco Systems (CSCO) trades at $113.98, up 1.14% on the day, with a technical picture showing bearish momentum indicators but recent positive earnings beats. The company reported Q1 2026 EPS of $1.06, beating expectations of $1.03, continuing a trend of outperformance. Recent news highlights Cisco's strategic push into AI cybersecurity, announcing new software tools and partnerships at Cisco Live 2026. Valuation metrics appear elevated with a P/E of 37.99 and P/S of 7.48, though profitability remains strong with a 64.33% gross margin.
The outlook balances strong analyst support (52% buy ratings with $130.38 consensus target) against high valuation multiples and mixed technical signals. Investment opportunity centers on Cisco's AI infrastructure and cybersecurity positioning, while risks include execution in transitioning growth drivers, competitive pressures, and potential margin compression if revenue growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
